12 July 2020 : Database Analysis
Clinical Features and Prognosis of Merkel Cell Carcinoma in Elderly Patients
YiJun Xia1ABE, DongSheng Cao1BD, Jun Zhao2C, BangZhong Zhu1D, Juan Xie1ADEF*DOI: 10.12659/MSM.924570
Med Sci Monit 2020; 26:e924570
Table 1 General characteristics of elderly patients with Merkel cell carcinoma.
| Variables | Age | P value | |
|---|---|---|---|
| 65–80 years | >80 years | ||
| Race | 0.899 | ||
| White | 1056 (96.2%) | 838 (95.8%) | |
| Black | 14 (1.3%) | 11 (1.3%) | |
| Other | 25 (2.3%) | 22 (2.5%) | |
| Unknown | 3 (0.3%) | 4 (0.5%) | |
| Sex | 0.031 | ||
| Male | 723 (65.8%) | 535 (61.1%) | |
| Female | 375 (34.2%) | 340 (38.9%) | |
| Marital status | <0.001 | ||
| Single | 314 (28.6%) | 379 (43.3%) | |
| Married | 721 (65.7%) | 424 (48.5%) | |
| Unknown | 63 (5.7%) | 72 (8.2%) | |
| Primary site | <0.001 | ||
| Face/head/neck | 401 (36.5%) | 460 (52.6%) | |
| Trunk | 107 (9.7%) | 87 (9.9%) | |
| Upper and lower extremities | 523 (47.6%) | 305 (34.9%) | |
| Other | 67 (6.1%) | 23 (2.6%) | |
| Tumor size | <0.001 | ||
| No mass/tumor found | 71 (6.5%) | 19 (2.2%) | |
| 1–10 mm | 338 (30.8%) | 247 (28.2%) | |
| 11–20 mm | 311 (28.3%) | 279 (31.9%) | |
| 21–30 mm | 168 (15.3%) | 148 (16.9%) | |
| 31–40 mm | 85 (7.7%) | 66 (7.5%) | |
| 41–50 mm | 55 (5.0%) | 44 (5.0%) | |
| >50 mm | 64 (5.8%) | 62 (7.1%) | |
| Unknown | 6 (0.5%) | 10 (1.1%) | |
| T stage | <0.001 | ||
| T0 | 66 (6.0%) | 17 (1.9%) | |
| T1 | 642 (58.5%) | 513 (58.5%) | |
| T2 | 291 (26.5%) | 240 (27.4%) | |
| T3 | 55 (5.0%) | 50 (5.7%) | |
| T4 | 44 (4.0%) | 55 (6.3%) | |
| N stage | 0.005 | ||
| N0 | 696 (63.4%) | 610 (69.7%) | |
| N1 | 371 (33.8%) | 236 (27.0%) | |
| N2 | 31 (2.8%) | 29 (3.3%) | |
| M stage | 0.101 | ||
| M0 | 1043 (95.0%) | 816 (93.3%) | |
| M1 | 55 (5.0%) | 59 (6.7%) | |
| Primary site surgery | 0.119 | ||
| No | 110 (10.0%) | 111 (12.7%) | |
| Yes | 987 (89.9%) | 764 (87.3%) | |
| Unknown | 1 (0.1%) | 0 | |
| Scope regional lymph node surgery | <0.001 | ||
| None | 300 (27.3%) | 486 (55.5%) | |
| Regional lymph nodes removed | 305 (27.8%) | 173 (19.8%) | |
| Sentinel lymph node biopsy | 393 (35.8%) | 163 (18.6%) | |
| Sentinel lymph node biopsy+regional lymph nodes removed | 91 (8.3%) | 43 (4.9%) | |
| Unknown | 9 (0.8%) | 10 (1.1%) | |
| Regional nodes examined | <0.001 | ||
| No | 326 (29.7%) | 502 (57.4%) | |
| Yes | 770 (70.1%) | 372 (42.5%) | |
| Unknown | 2 (0.2%) | 1 (0.1%) | |
| Regional nodes positive | <0.001 | ||
| No | 422 (38.4%) | 167 (19.1%) | |
| Yes | 347 (31.6%) | 205 (23.4%) | |
| No nodes examined | 326 (29.7%) | 502 (57.4%) | |
| Unknown | 3 (0.3%) | 1 (0.1%) | |
| Radiation | <0.001 | ||
| No | 481 (43.8%) | 536 (61.3%) | |
| Yes | 617 (56.2%) | 339 (38.7%) | |
| Chemotherapy | <0.001 | ||
| No/unknown | 950 (86.5%) | 831 (95.0%) | |
| Yes | 148 (13.5%) | 44 (5.0%) | |
| Bone metastasis | 0.003 | ||
| No | 1085 (98.8%) | 851 (97.3%) | |
| Yes | 12 (1.1%) | 13 (1.5%) | |
| Unknown | 1 (0.1%) | 11 (1.3%) | |
| Brain metastasis | 0.013 | ||
| No | 1095 (99.7%) | 863 (98.6%) | |
| Yes | 1 (0.1%) | 1 (0.1%) | |
| Unknown | 2 (0.2%) | 11 (1.3%) | |
| Liver metastasis | 0.004 | ||
| No | 1079 (98.3%) | 849 (97.0%) | |
| Yes | 18 (1.6%) | 15 (1.7%) | |
| Unknown | 1 (0.1%) | 11 (1.3%) | |
| Lung metastasis | 0.002 | ||
| No | 1087 (99.0%) | 852 (97.4%) | |
| Yes | 10 (0.9%) | 11 (1.3%) | |
| Unknown | 1 (0.1%) | 12 (1.4%) | |